SCHEMBL2220908

SCHEMBL2220908

O=C(O)c1ccc2c(=O)c3c([nH]c2c1)CCCC3

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
HSD17B10 Q99714 3/20 0.52
MAPT P10636 4/20 0.52
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
LMNA P02545 2/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
HPGD P15428 1/20 0.52
HTT P42858 1/20 0.52
POLB P06746 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
PARP1 P09874 3/20 0.48
F2 P00734 1/20 0.45
TP53 P04637 1/20 0.44
CASP1 P29466 1/20 0.44
CSNK2A1 P68400 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14651018 0.99 SMN1; SMN2 (0.58) ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT
SCHEMBL2484751 0.90 MAPT (0.63) ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT
SCHEMBL30201480 0.90 MAPT (0.63) ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT
SCHEMBL14635243 0.89 HSD17B10 (0.63) ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT
SCHEMBL1586929 0.81 MAPT (0.70) ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT
SCHEMBL29643236 0.81 MAPT (0.70) ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT
SCHEMBL10738593 0.79 MAPT (0.68) ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT
SCHEMBL4283723 0.78 MAPT (0.66) ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT
SCHEMBL18705660 0.77 KMT2A (0.44) ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT
SCHEMBL30571064 0.77 MAPT (0.62) ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
EP-2523938-B1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2014-09-03 EP disclosed
EP-2523938-B1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2014-09-03 EP disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
EP-2523938-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Hybrigenics S.A. (FR) 2012-11-21 EP disclosed
EP-2357176-A1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 Hybrigenics S.A. (FR) 2011-08-17 EP disclosed
EP-2357176-A1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 Hybrigenics S.A. (FR) 2011-08-17 EP disclosed
US-20110177105-A1 Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications HYBRIGENICS SA (FR) 2011-07-21 US disclosed
US-20110177105-A1 Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications HYBRIGENICS SA (FR) 2011-07-21 US disclosed
US-20110177105-A1 Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications HYBRIGENICS SA (FR) 2011-07-21 US disclosed
WO-2011086178-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2011-07-21 WO disclosed
WO-2011086178-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110177105-A1 Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications USP7, SENP7, PSMA7 ALDH1A1 3216/4885KDM4E 1224/4885SMN1; SMN2 2877/4885
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 ALDH1A1 3216/4885KDM4E 1224/4885SMN1; SMN2 2877/4885
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 ALDH1A1 3216/4885KDM4E 1224/4885SMN1; SMN2 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.